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Molecular imaging has witnessed a tremendous change over the last decade. Growing interest and emphasis are placed on
this specialized technology represented by developing new scanners, pharmaceutical drugs, diagnostic agents, new therapeutic
regimens, and ultimately, signiﬁcant improvement of patient health care. Single photon emission computed tomography (SPECT)
and positron emission tomography (PET) have their signature on paving the way to molecular diagnostics and personalized
medicine. The former will be the topic of the current paper where the authors address the current position of the molecular
SPECT imaging among other imaging techniques, describing strengths and weaknesses, diﬀerences between SPECT and PET,
and focusing on diﬀerent SPECT designs and detection systems. Radiopharmaceutical compounds of clinical as well-preclinical
interest have also been reviewed. Moreover, the last section covers several application, of μSPECT imaging in many areas of disease
detection and diagnosis.
1.Introduction
Small animal imaging has become an integral part of molec-
ular medicine. Translation of ideas from bench to the clinic
needs a veriﬁcation and validation step where molecular
diagnostic modalities are substantial tools in developing new
tracers, drug design and therapeutic regimens. In the last
few years, there was a tremendous change and focus on the
development of new microscale imaging systems of spatial
resolution and detection sensitivity that relatively cope with
the requirements of imaging small animals such as mice
and rats. The focus was not only on instrumentation but
also was accompanied by contrast agents/probes/biomarkers
that target speciﬁc biological processes. Similarly, as these
molecular agents are developed to suit particular biochem-
ical targets, there are corresponding imaging techniques
able to detect this particular signal. There is a relatively
large array of imaging modalities that have their individual
characteristics. The molecular imaging arena has been revo-
lutionized also by hybridization/fusion of these techniques
into single imaging devices. The best example that can be
drawn from the literature as well as from the clinical practice
is the recent implementation of PET/CT and (SPECT/CT)
in clinical oncology and other important areas of disease
detection. Apparent PET/MRI implementation and direct
incorporation in routine practice is still controversial and
active research is underway and its spread in the market will
be determined in the near future [1].
However, there are emerging promising approaches that
are undergoing extensive research work and investigation
(with some successful results) for possible translation into
the clinic. These include contrast-enhanced molecular ultra-
sound with molecularly targeted contrast microbubbles,
optical imaging with ﬂuorescent molecular probes, Raman
spectroscopy/microscopy and more recently, photoacoustic
imaging; a hybrid optical and ultrasound technique (see [2–
4] for review).
Nuclear medicine has an established role in this context
and tomographic tools such as single photon emission
computer tomography (SPECT) and Positron Emission
Tomography (PET) have their signiﬁcant contribution to
the world of molecular imaging [4, 5]. However, anatomical2 International Journal of Molecular Imaging
techniques such as CT and MRI through their high spa-
tial resolution capabilities serve to identify morphological
changes in small structures. When these imaging modalities
are combined in one imaging session, the amount of infor-
mation obtained can synergically and signiﬁcantly improve
the diagnostic process and its outcome when compared to a
single diagnostic technique [6].
Another important aspect of preclinical imaging is the
ability to study the physiology over several time points
referred to as longitudinal studies. A signiﬁcant reduction of
cost, number of animals as well as reduction of intervariabil-
ity among subjects are among the most important outcomes
of this technology. Thus, one can avoid animal dissection, ex
vivo tissue counting and other autoradiographic studies.
2. Instrumentation
2.1. Strengths and Weaknesses. Diagnostic modalities can
generally be distinguished based on whether they are
structural or functional imaging techniques. Computerized
tomography (CT) and magnetic resonance imaging (MRI)
are well-known diagnostic tools that provide very high
structuralinformationofthetissueunderinvestigationwhen
compared to functional techniques such as SPECT or PET.
MRI provides better soft tissue contrast even in absence of
contrast media, a feature that is absent in CT scanning.
Ultrasoundproceduresusehigh-frequencyultrasoundwaves
to diﬀerentiate between diﬀerent anatomical structures and
safe (radiationless) diagnostic imaging technique. However,
it has less functional or physiological signiﬁcance when
compared to nuclear modalities. Optical imaging such as
bioluminescenceandﬂuorescencearealsofunctionalmodal-
ities, but their limited spatial resolution, limited penetration
capabilities and other factors contribute to their unease of
transition to clinical practice [3].
The relative weaknesses and strengths that exist among
imagingtechniquesareimportanttobeunderstood.Onecan
notice that the spatial resolution of MRI and CT is signif-
icantly higher than that of SPECT and PET. However, the
detectionsensitivityofSPECTandPETissigniﬁcantlyhigher
than those given by structural modalities and moreover can
detect tracer concentration in the picomolar or nanomolar
range. Both approaches use the tracer principal to detect
physiological abnormality or disturbed biochemical process.
The key elements in radionuclide imaging are a bio-
marker and an imaging device. The ﬁrst should have high
speciﬁc, as well as sensitive characteristics to optimally study
a molecular or cellular phenomenon. The imaging device
is a radiation detector with speciﬁc performance to localize
activity distribution within the human body or the animal.
The most commonly used instrument in SPECT imaging
is the conventional gamma camera that was invented in
the middle of the last century by Anger [7]. However, for
detection of coincidence events and localization of PET-
administered compounds, a PET scanner is normally used.
Both imaging devices have witnessed a signiﬁcant change in
thelastdecadeintermsofperformancecharacteristicsaswell
as diagnostic quality.
On the other hand, MRI techniques do not relay on
ionizing radiation, and thus, it is one of the features
that characterize magnetic resonance procedures over other
methods. Because of these inherent diﬀerences, there has
been a large interest to combine more than one or two
modalities into one imaging system able to morphologically
and functionally address pathophysiologic questions. The
present review will generally discuss many aspects of small
animal micro-SPECT (μSPECT) imaging including instru-
mentation, molecular imaging probes used in preclinical
and clinical practice, and the last section will cover some
important and valuable preclinical applications. Before this
discussion, the author would like to outline some major
diﬀerences that exist between SPECT and PET imaging.
2.2. SPECT versus PET. In clinical practice, almost all
nuclearmedicineproceduresthatusesinglephotonemission
tracers rely on the use of the gamma camera. It is a gamma
ray position sensitive detector that typically consists of large
slab of scintillator crystal with position circuitry and energy
determination. To localize the emission site of the released
photons, a multihole collimator is mounted on the front face
of the system to provide a spatial correlation of the detected
events.
Hal Anger introduced the gamma camera as a novel
detection technique able to localize an activity distribution
of an administered radionuclide. However, his original
prototype in 1953 was a camera in which a photographic
X-ray ﬁlm was in contact with NaI(Tl) intensifying screen.
He used a pinhole collimation and small detector size to
project the distribution of gamma rays onto the scintillation
screen [7]. Initially, the camera was used to scan patients
administered by therapeutic doses of 131-I. Disadvantages of
this prototype were (1) small ﬁeld of view of the imaging
system (4 inch in diameter) and (2) poor image quality
unless a high injected dose or long exposure time are
applied. In 1958, Anger succeeded in developing the ﬁrst
eﬃcient scintillation camera, and marked progress in the
detection eﬃciency was realized by using an NaI(Tl) crystal,
photomultiplier (PMT) tubes, and a larger ﬁeld of view.
Spatial resolution and detection sensitivity are two
important performance characteristics that play an impor-
tant role in molecular imaging research using SPECT and
PET tracers. Although the clinical gamma camera can
provide a tomographic resolution of about 10mm, some
preclinical SPECT scanners can provide a submillimeter
spatial resolution pushing down to subhalf millimeters using
a specialized dedicated multipinhole geometry [8]. This
situation is diﬀerent in clinical and preclinical PET imaging
where the spatial resolution of preclinical PET scanners is
about 1-2mm while that of clinical PET scanners lies in the
range of 4–6mm. Dedicated brain PET scanners, however,
can achieve a slightly better spatial resolution (≈2.5mm)
in the centre ﬁeld of view. These resolution diﬀerences are
mainly due to the fact that SPECT systems are not aﬀected
by some physical and fundamental limits that hinder the
PET camera to reach sub-millimeter ranges although some
research groups were able to achieve a resolution of less thanInternational Journal of Molecular Imaging 3
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Figure 1: Spatial resolution across the clinical and preclinical SPECT and PET imaging scanners.
1mm using ﬁne segmented lutetium orthosilicate (LSO)
crystal [9]. Figure 1 clearly deﬁnes the position of μSPECT
in the molecular imaging matrix.
Many factors serve to impact the ﬁnal reconstructed
images of data acquired from a PET scanner. These are
crystal size, positron range, photon acollinearity, intercrystal
interaction and scatter, depth of interaction and the recon-
struction algorithm. In preclinical PET machines, positron
range appears to be the most important challenge that
needs to be tackled to improve the spatial resolution of
the PET images. However, the current generation of clinical
PET scanners is slightly aﬀected by the positron range, but
correction of the phenomenon was shown to be eﬀective
in positron emitters of high maximum kinetic energy [10–
12]. These issues are obviously absent in clinical as well as
preclinical SPECT systems. The gamma camera relies on
hardware collimators to determine the photons trajectory
and hence able to localize the emission site by analyzing
the electronic signal detected by the imaging detector. This
hardware collimation plays a signiﬁcant role in reducing the
overall system sensitivity as well as the spatial resolution.
The intrinsic resolution of gamma camera is about 3-
4mm and tomographic SPECT acquisition reveals a spatial
resolution, as mentioned above, not better than 10mm.
However, a new trend of designing semiconductor systems is
emergingintheﬁeld,providingasigniﬁcantimprovementin
spatial resolution, and other performance measures [13, 14].
SPECT degrading factors have been extensively studied
intheliteratureand, namely,include attenuation,scatterand
resolutioneﬀects,inadditiontomotionartifacts.Apartfrom
the later, most of these physical issues can be resolved in
great part by the use of SPECT/CT systems. These imaging
degrading factors have a relatively smaller impact on the
overall image quality in small animal imaging due to the
smaller size of the rodents (mouse 20–40g, rat 250–550g)
in comparison to standard human (75kg). Nevertheless,
correctionforphotonattenuation,scatterandpartialvolume
would collectively improve the detection and estimation task
[15]. This is particularly important for small structures and
in small energy radionuclides such as I-125 [16].
Unlike PET, single photon emitting radiopharmaceuti-
cals have several features in the context of molecular imaging
such as cost and wide availability of the radioligands as
well as relative ease of labeling. Small animal imaging using
preclinical scanners and PET radiopharmaceuticals showed
better capability in tracer kinetic studies when compared
to its SPECT counterparts. PET compounds have been
extensively used in compartmental modeling and kinetic
analysis. Furthermore, small animal PET scanners showed a
large axial ﬁeld of view such that distant tissues/organs can
be covered when image derived input function such as left
ventricle is sought for calculations.
2.3. Pinhole Geometry: Pros and Cons. Hal Anger used a
pinhole collimation which is an important element when we
come across μSPECT imaging. The early work done on small
animal imaging using SPECT tracer was to use a gamma
camera equipped with pinhole collimator(s) of very small
aperture size. Although parallel hole is the most commonly
used collimator in many nuclear medicine procedures,
pinhole imaging has a well-recognized role particularly for
small organs such as thyroid and parathyroid imaging. In
bone joints as well as in some pediatric studies, pinhole
can also improve the spatial resolution by magnifying small
structures of diﬀerent tracer uptakes.
In recent years, pinhole geometry was found an increas-
ing interest in designing SPECT scanners with superb spatial
resolutionandthishasbeenattainedbyminimizingtheaper-
ture size to sub-millimeter range and specialized collimator
geometry. However, the cost paid for this improved spatial
resolution is a reduction of the detection eﬃciency. The
later was partially tackled by increasing the number of holes
for improvement of count collection and statistical quality.
Pinhole geometry is not similar to parallel hole geometry
where one-to-one magniﬁcation is achieved. The geometric
magniﬁcation provided by pinhole geometry is a function of
theobjectdistancefromtheapertureaswellasdistanceofthe
aperture from the detector surface in addition to the eﬀective
aperture diameter. Nothing is free, this takes place with a
reduction of the imaging ﬁeld of view. Another problem
encounteredwhenpinholecollimatorisusedintomographic
acquisition is data insuﬃciency and the resulting images
could suﬀer from reconstruction errors.
Image reconstruction using iterative techniques have
solved many problems that were not possible to achieve with
analytic approaches. In clinical and preclinical arena involv-
ing both SPECT and PET imaging, iterative reconstructions
were found superior to analytic approaches in many aspects
of diagnostic quality and quantitative accuracy. μSPECT
imaging has received large beneﬁt from the use of iterative
reconstruction by incorporating as many degrading factors
in the system matrix. Besides its treatment to image noise,
iterative reconstruction for pinhole geometry can correct for
photon attenuation, scatter, and system response function.
Edge penetration and parallax errors can also be modeled
in the reconstruction scheme reducing the blurring eﬀect
allowing for enhanced spatial resolution [17].4 International Journal of Molecular Imaging
2.4. Detectors. A conventional gamma camera can be used
by manufacturing pinhole collimators of very small aperture
size.Itprovideslargeﬁeldofviewsuchthatbettermagniﬁca-
tion can be achieved. The other alternative is to use pixilated
detectors that have better intrinsic properties or semicon-
ductor detectors that ﬁt with the resolution requirements
of small animal imaging and, meanwhile, better than that
provided by the conventional gamma camera. Regardless of
their cost, semiconductor detectors are more compact and
allow for system portability and can be manufactured in
pixilated structure providing better spatial resolution.
Using a large ﬁeld of view gamma camera serves to
improvethemagniﬁcationbyprovidinglargeprojectionarea
onto the detector surface for the subject under investigation.
However, some recent scanners are implementing pixilated
detectors that have an intrinsic resolution equivalent to the
segmentation size. This, to some extent, obviates the need
to use detector width of size equivalent to the standard clin-
ical gamma camera [5]. Thallium-activated sodium iodide
NaI(Tl) crystal is the conventional scintillator used in most
clinical designs. However, there are also some scintillators
that have been used such as Cesium Iodide-Thallium doped
and Cesium Iodide-Sodium doped and Yttrium Aluminum
Perovskite (CsI(Tl), CsI(Na), and YAP, resp.). New designs
of photodetectors such as position sensitive PMT, avalanche
photodiode and position sensitive avalanche photodiode can
be of value in μSPECT systems. For example, Funk et al.
[18] have designed a multipinhole small animal imaging
based on position sensitive avalanche photodiode (PSAPD)
detectors coupled to CsI(Tl) scintillator. The system showed
submillimeterspatialresolutionandhighdetectioneﬃciency
when compared to dual head gamma camera, permitting
shortened acquisition time and a reduced injected dose.
2.5. Designs. Several designs were proposed for pinhole
geometry, including rotating gamma camera, stationary
detector but rotating collimators, or completely stationary
camera [19]. In U-SPECT II (MILabs, The Netherlands), the
three-headed gamma cameras is equipped with interchange-
able multihole collimators that can achieve high spatial
resolution [20]. The collimator is cylindrical in shape with
relatively large number of pinholes (i.e., 75), providing a
good count collection for the high spatial resolution. A
resolution of 0.35mm can be achieved with an aperture
size of 0.35mm while a spatial resolution of 0.45mm can
be obtained with a 0.6mm gold pinhole aperture size. The
values are less in case of rat imaging (0.8mm) using the
standard whole body rat collimator. A recent release of the
MILab company is the simultaneous acquisition of SPECT
and PET tracers with resolution that can reach below 1mm
for the former [21].
The Inveon is another commercial design provided by
Siemens Medical Solutions. The scanner is a trimodality
imaging system that has three imaging modules namely
PET, SPECT and CT. The SPECT and CT are coplanar and
mounted on the same rotating gantry. The SPECT portion
can be two or four 150mm × 150mm NaI(Tl) pixilated
detectors (2.2mm pitch) and 10mm crystal thickness. The
heads can be equipped with various parallel-hole, single-
or multipinhole collimators, including mouse general body
as well as mouse brain imaging with possible submillimeter
spatial resolution.
Another two commercial μSPECT designs provided
by Gamma-Medica Ideas and Bioscan. The Triumph Tri-
modality scanner (Gamma Medica, Inc) is an integrated
SPECT/PET/CT hardware and software platform designed
for small animals in preclinical and biomedical research
applications. The system combines PET (LabPET), SPECT
(X-SPECT) and CT (X-O) modalities. The SPECT module
utilizes solid-state cadmium zinc telluride (CZT) detector
technology. It provides opportunities to scan individual
organs or whole body images. The SPECT system accom-
modates single and multiple pinhole collimators as well as
parallel hole collimators to address a broad range of study
needs. It can be conﬁgured to have 1,2,3 or 4 CZT cameras
providing a variety of spatial resolution, detection sensitivity,
and scanning ﬁeld of view [20].
The Bioscan system has a four-detector head that consist
ofNaI(Tl)crystal.Thescannerusesthespiralpathtoscanthe
object (24 to 270mm) and also has stationary and circular
detector motion. It has a variety of collimator options that
can reach <1mm spatial resolution in addition to high
detection sensitivity [22]. It uses a patented multiplexed-
multipinhole collimator design that can reach 36 pinholes
or eve more. Commercially available μSPECTs are shown in
Figure 2.
2.6. Hybrid SPECT Systems. μSPECT scanners can produce
functional images with high spatial resolution; however,
anatomical correlation using structural imaging modalities
is still needed. For this reason, CT or MRI have been incor-
porated in some μSPECT systems. In addition to SPECT/CT
andSPECT/MRIotherhybridsystemssuchasSPECT -optical
devices have also been investigated [23, 24]. The common
underlying idea is to get and extract more information
about the biological question in one imaging session and
preferablywith the same spatial and/or temporal framework.
Figure 3 shows bone imaging in mouse using an SPECT/CT
preclinical scanner. CT devices provide several advantages to
the SPECT. They produce high resolution anatomical images
in addition to generating a subject-speciﬁc attenuation map
able to correct for photon attenuation. MRI machines can
have a better soft tissue contrast, not relying on ionizing
radiation, and provide high spatial resolution as mentioned
earlier.
microCT (μCT) has been advanced in the last few years
providing a spatial resolution in the order of few microns.
Ar e s o l u t i o no f1 0μm or even better can be achieved giving
more insights into structural abnormalities for in vivo as
well as ex vivo samples. Nowadays, μCT is not only for
attenuation and anatomical localizations but the beneﬁts
were extended to blood vessels imaging which is known as
CT angiography. A number of reports were recently released
discussing the utility of μCT in many preclinical applications
[25, 26]. SPECT/MRI systems were also designed, and it
is worthy mentioning that image of the year 2008 (in the
annual meeting of the Society of Nuclear Medicine) was
selected where diabetic feet using SPECT were coregisteredInternational Journal of Molecular Imaging 5
μSPECT imaging
SPECT/ACT imaging
(a) (b) (d)
(c)
Figure 2: Invivo SPECT and SPECT/CT with 99mTc-MDP in C57BL/6 mice (3hrs after injection dose 120MBq i.v.). Note the high uptake
in glenohumeral, the hip, and the femorotibial joints as shown in the whole body mouse (a). In (b) and (c), upper and lower extremities are
shown where SPECT and CT images are coregistered. The whole body fused SPECT and CT is shown in (d). Images were acquired with the
Inveon system (Siemens Medical Solutions) using dual detectors each mounted with a 5-pinhole collimator. The pinhole aperture size was
1.0mm.
(a) (b) (c)
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Figure 3: Some commercial preclinical SPECT systems. (a) A preclinical hybrid PET/SPECT device, the VECTor (Image courtesy of MI
Labs), (b) Triumph Trimodality scanner (courtesy of Gamma Medica), (c) NanoSPECT (courtesy of BioScan, Inc), and (d) Inveon system
(courtesy of Siemens Medical Solution) with internal components demonstrated (courtesy of Siemens Medical Solution).6 International Journal of Molecular Imaging
with the patient MRI providing anatomolecular diagnosis of
the extent and location of the disease. In preclinical context,
the interest was given to PET/MRI rather than SPECT/MRI.
However, new photodiodes that are less prone to magnetic
ﬁelds can be very helpful in such designs.
3.Radiopharmaceuticals
Molecular imaging is an emerging ﬁeld of study that deals
with imaging of disease on a cellular or genetic level rather
t h a no nag r o s sl e v e l[ 27]. With the emergence of the new
ﬁeld of molecular imaging, there is an increasing demand
for developing sensitive and speciﬁc novel imaging agents
that can rapidly be translated from small animal models into
patients.SPECTandPETimagingtechniqueshavetheability
to detect and serially monitor a variety of biological and
pathophysiological processes, usually with tracer quantities
of radiolabeled peptides, drugs, and other molecules at doses
free of pharmacologic side eﬀects [28].
3.1. Radiolabeled Molecular Imaging Probes (RMIPs). RIMPs
are highly speciﬁc radiolabeled imaging agents used to
visualize, characterize, and measure biological processes in
living systems. Both, endogenous molecules and exogenous
probes can be molecular imaging agents. The ultimate
goal of molecular medicine is to treat the disease in its
early stages with an appropriate patient-speciﬁc “targeted
molecular therapy.” In order to achieve this goal, it is
essential to develop highly speciﬁc RMIPs. In the design and
development of an ideal RMIP, it is important to identify
ﬁrst a molecular imaging probe (MIP), which may be a
biochemical or a synthetic molecule, speciﬁc for a biological
process (such as metabolism, angiogenesis, and apoptosis)
or a molecular target (such as hexokinase, thymidine kinase,
and neuroreceptor) in an organ, or tissue of interest.
GeneralRulesfortheDesignof RMIPs. AnidealRMIPshould
be designed to fulﬁll the following characteristics [29].
(i) Rapid plasma clearance to reduce blood pool back-
ground in the target tissue.
(ii) Rapid washout or clearance from non speciﬁc areas.
(iii) Low nonspeciﬁc binding and preferably no periph-
eral metabolism.
(iv) High membrane permeability and intracellular trap-
ping.
(v) Target speciﬁcity and high aﬃnity for molecular
targets.
(vi) Speciﬁc activity must be high to prevent saturation of
speciﬁc binding sites.
(vii) Tissue distribution, localization, and target binding
should be favorable for developing simple kinetic
modeling to estimate quantitative data.
(viii) Radiation dosimetry of RMIP must be favorable for
multiple diagnostic imaging studies (if necessary).
(ix) Synthesis of RMIP must be rapid and suitable for
automation using automated synthesis modules.
Radiolabeling of RMIPs. Generally, the radiolabeling process
of molecular imaging agents can be categorized as follows.
Isotope Exchange. Where the preparation is obtained by
direct exchange of stable atom(s) of an element in a molecule
with one or more nuclide of a radioisotope of the same
element.
Introduction of Foreign Element. This is the most common
method of radiolabeling of RMIPs, however, the RMIP will
haveachemicalstructureandinvivobehaviordiﬀerentfrom
that of the parent MIP.
Metal Chelation. In this method, a chelating agent (radio-
metal such as 99mTc and 111In) is being introduced into
an organic compound producing a ligand with diﬀerent
biological and chemical features than both the conjugated
two partners. Certain peptides and monoclonal antibodies
can successfully be labeled by the metal chelation procedure
but only in the presence of a bifunctional chelate (BFC) by
conjugation with the peptide or protein ﬁrst and then bind
the radiometal to the BFC conjugated molecule.
ClassiﬁcationofRMIPs. Basedontheirclinicalutilityandthe
nature of application for which they are designed as tools in
the drug development program, four classes of RMIPs have
been identiﬁed [30].
(a) Radiolabeled drug substance in which the cold stable
atom is replaced by a radioisotope of the same
element, which can be used for assessing the phar-
macokinetics and biodistribution of the parent drug.
(b) Radioligand with good binding aﬃnity for a biologi-
cal target, which can be used to evaluate the eﬀect of
other unlabeled compounds at that target.
(c) Pathway marker interacting with one component of a
setofrelatedbiologicalmolecules,whichmaybeused
to probe the overall status of that system.
(d) Biomarker,o rs u r r o g a t em a r k e r ,w h i c hp r o v i d e sa
more general readout at the level of cell or organ for
a speciﬁc biological process.
3.1.1. Peptides and Proteins
(1) Radiolabeled Monoclonal Antibodies (MAbs). Antibodies
are immunoglobulins (Ig) produced in vivo in response to
the administration of an antigen to a human or animal tissue
and bind speciﬁcally to this antigen forming an antigen-
antibody complex [31]. Since the advent of hybridoma
technology for production of MoAbs in 1975 [32] which was
designedoriginallyasaninvivotumorlocalizingagents,only
few have reached a point of proven clinical utility [33].
Labeling of MAbs can be accomplished with several
radionuclides, among which In-111, Tc-99m, I-131, I-123,
andI-125,wheremostofthemarecommonlyusedinnuclear
medicine[34]andlistedinTable 1.Anumberofmonoclonal
labeled antibodies using In-111 or Y-90 radionuclides are
described in Table 2.International Journal of Molecular Imaging 7
Table 1: Commonly used single photon emitting radionuclides.
Radionuclide Half-life Energy Mode of decay
Tc-99m 6.02h 142keV IT (100%)
I-131 8.03 days 364keV β− (100%)
I-123 13.22h 159keV EC (100)
In-111 2.80 days 171, 245keV EC (100%)
IT: isomeric transition, β−:b e t a - m i n u s ,E C :e l e c t r o nc a p t u r e .
(2) 99mTc-labeled Monoclonal Antibodies
Arcitumomab (CEA Scan). Carcinoembryonic Antigen
(CEA) or CEA-Scan kit (introduced by Mallinckrodt
Medical) as a single dosage kit contains the active ingredient
Fab− fragment of arcitumomab, a murine monoclonal
antibody IMMU-4. CEA is expressed in a variety of
carcinomas, particularly of the gastrointestinal tract (GIT)
and can be detected in the serum. IMMU-4 is speciﬁc for the
classical 200kDa CEA that is found predominantly on the
cell membrane. 99mTc-CEA-Scan complexes the circulating
CEA and binds to CES on the cell surface. Fab− fragment of
arcitumomab is cleared rapidly by urinary tract and plasma
clearance due to its small particular size [38]. The IMMU-4
antibody is targeted against the carcinoembryonic antigens
of the colorectal tumors, and, therefore, 99mTc-CEA-scan
is used for the detection of recurrence and/or metastatic
carcinomas of the colon or rectum particularly when high
levels of CEA are detected [39]. However, it is an uncommon
procedure following PET/CT scan.
Sulesomab (LeukoScan). The kit vial contains the active in-
gredientFab− fragment,calledsulesomab,obtainedfromthe
murinemonoclonalantigranulocyteantibody,IMMU-MN3.
It is a single-dose kit introduced by Immunomedics Europe
in 1997. The labeling yield should be more than 90% [40].
99mTc-sulesomab targets the granulocytes, and therefore is
primarily used to detect infection and inﬂammation, partic-
ularlyinpatientswithosteomyelitis,jointinfectioninvolving
implants, inﬂammatory bowel disease, and diabetic patients
with foot ulcers [41].
Annexin V (Apomate). Annexin V is a human protein with
a molecular weight of 36kDa has a high aﬃnity for cell
membranes with bound phosphatidyl serine (PS) [42]. In
vitro assays have been developed that use Annexin V to
detect apoptosis in hematopoietic cells, neurons, ﬁbroblasts,
endothelial cells, smooth muscle cells, carcinomas, and
lymphomas. 99mTc-annexin V has also been suggested as an
imaging agent to detect thrombi in vivo, because activated
platelets express large amounts of PS on their surfaces [43].
(3) Radiolabeled Peptides. High background activity diﬃcul-
ties which usually appear when imaging with radiolabeled
MAbs which is attributed to the slow tumor uptake and
plasma clearance due to their relatively large molecular sizes.
This can be mitigated by peptides whose molecular size is
smallerthanthatofproteinsandwherethepeptidasescanact
for rapid excretion by degradation of the peptides. Peptides
havebeenlabeledwith 111Inand 99mTcinthesamemannerof
the monoclonal antibodies. Some useful labeled compounds
are listed in Table 3.
3.1.2. RMIPs for Metabolism. Metabolic imaging can be
achieved using natural or exogenous radiolabeled substrates
which participate in the particular metabolic process. The
design of such tracers is based on the physiological concepts
such as turnover of oxygen, glucose, amino acids, fatty acids,
or DNA precursors. Commonly, 123Ia n d99mTc derivatives
are used as SPECT tracers for this function, however, the
obvious chemical changes occur with this conjugation which
can alter the physiological properties of the tracer module
limits their application in molecular imaging.
(1) Glucose Metabolism. Although there are intensive
research trials to ﬁnd a sugar derivative labeled with 123I
and 99mTc, none of these were able to provide an SPECT
substitute for 18F-FDG to act as glucose metabolism imaging
agent [51–53].
(2) Amino Acid Metabolism. Diagnosis of various neurologi-
cal diseases as well as tumor evaluation (detection, grading
and therapy monitoring) can be obtained by quantitative
assessment of protein synthesis rate that is provided when
using radiolabeled amino acids as a radiolabeled molecular
imaging probe (RMIP). Radiolabeled amino acids pass the
blood-brain barrier and are accumulated in tissues via a
speciﬁc amino acid transport system [54]. L-3-123I-Iodo-α-
methyltyrosine (123I-IMT) is a good example of radiolabeled
amino acids, it is evidenced that it accumulates in the brain
via a speciﬁc facilitating L-amino acid transport system. In
analogywithPET,IMTisnotincorporatedintoproteins[55]
and its uptake reﬂects amino acid transport [56]. IMT can be
prepared by electrophilic substitution via in situ oxidation of
123I-Iodide by chloramines-T, hydrogen peroxide, iodogen,
or iodate with radiochemical yields of 70%–80%.
(3) Nucleosides Metabolism (Gene Reporter Imaging). Nucle-
osides or nucleoside analogs can be transported across the
cell membrane by selective transporters and can then be
phosphorylated intracellularly by speciﬁc kinases to the
corresponding phosphate derivatives, and, ultimately, they
can be incorporated into DNA. As thymidine kinase 1 (tk1)
shows an S-phase dependant expression, the intracellular
accumulation of labeled nucleosides that are substrates for
TK1 reﬂects DNA synthesis and thus tumor proliferation. I-
131-[57] and I-124-[58] labeled 2-arabino-ﬂuro-5-iodo-2-
deoxyuridine (FIAU) has been used successfully as nucle-
oside analog for tumor proliferation detection. Nucleoside
derivatives that are selective substrates for herpes simplex
virus thymidine kinase (HSVtk) have been developed for
the in vivo visualization of transgene expression using the
HSVtk gene as a reporter gene. Radioiodine labeled uracil
compounds (e.g., FIAU) are widely applicable derivatives.8 International Journal of Molecular Imaging
Table 2: List of In-111- and Y-90-labeled monoclonal antibodies.
Compound Description Applications Remarks
In111-
Capromab
pendetide
(ProstaScint)
A conjugation between the
murine antibody 7E11.C5.3 and
111 In in the source of 111InCl3
by the action of the GYK-DTPA
as a chelating agent.
Indicated for use in
immunoscintigraphy, proven
prostate carcinoma and patients who
have undergone a prostatectomy and
have rising prostate speciﬁc antigen
(PSA) values and equivocal
nonevidenced metastasis.
It is not indicated with patients with a
high clinical suspicion of occult
metastatic disease or for screening of
prostate carcinoma.
In111-
Satumomab
pendetide
(OncoScint)
It contains the murine MAb
B72.3 which is directed to
tumor-associated glycoprotein.
It is labeled with 111InCl3 by
conjugation with the chelating
agent, GYK-DTPA.HCl.
Used for the detection of colorectal
and ovarian cancers [35].
After an incubation time of 30min, the
labeled mixture is suitable for use in the
ﬁrst 8 hours.
In111-
Imciromab
pentetate
(MyoScint)
An antibody produced against
myosin in the cell culture, and
therefore binds to the heavy
c h a i no fm y o s i na f t e ri nv i v o
administration.
Detection of myocardial infarction.
Contains the Fab fragment of a murine
monoclonal antibody that is covalently
bound to DTPA giving
111 In-Imciromab pentetate.
In-111 and Y90-
ibritumomab
tiuxetan
(Zevalin)
Zevalin consists of a murine
monoclonal anti-CD20
antibody covalently conjugated
to the metal chelator DTPA,
which forms a stable complex
with 111 In for imaging and with
90Yf o rt h e r a p y .
90Y-ibritumomab tiuxetan is used
for the treatment of some forms of B
cell non-Hodgkin’s lymphoma, a
myeloproliferative disorder of the
lymphatic system while its 111 In
derivative is used to scan the
predicted distribution of a
therapeutic dosage of
90Y-ibritumomab in the body [36].
The antibody binds to the CD20
antigen found on the surface of normal
and malignant B cells (but not B cell
precursors) allowing radiation from the
attached isotope (Yetrium-90) and the
cytotoxicity induced by the antibody
serve to eliminate B cells from the body
allowing a new population of healthy B
cells to develop from lymphoid stem
cells [37].
Rituximab
An earlier version of anti-CD20
antibody and has also been
approved under the brand
name Rituxan for the treatment
of non-Hodgkin’s lymphoma
(NHL).
It was approved for the treatment of
patients with relapsed or refractory,
lowgrade or follicular Bcell NHL,
including patients with rituximab
refractory follicular NHL.
In September 2009, ibritumomab
received approval from the FDA for an
expanded label for the treatment of
patients with previously untreated
follicular NHL, who achieve a partial or
complete response to ﬁrst-line
chemotherapy.
(4) Hypoxia Imaging. Hypoxia, a condition of insuﬃcient
O2 to support metabolism, occurs when the vascular supply
is interrupted, as in stroke or myocardial infarction, or
when a tumor outgrows its vascular supply. When otherwise
healthy tissues lose their O2 supply acutely, the cells usually
die, whereas when cells gradually become hypoxic, they
adapt by upregulating the production of numerous proteins
that promote their survival. These proteins slow the rate
of growth, switch the mitochondria to glycolysis, stimulate
growth of new vasculature, inhibit apoptosis, and promote
metastatic spread [59].
Most hypoxia markers contain a nitroimidazole moiety
as a reactive chemical species. Nitroimidazoles can be used as
probes to detect hypoxia as they are reduced intracellularly
in all cells, but in absence of adequate supply of O2,
they undergo further reduction to more reactive products
which bind to cell components and are ﬁnally trapped in
the hypoxic tissue [60]. 99mTc-O-propylene-amine-oxime
(99mTc-pano or BMS-181321) was validated as a proper
hypoxia imaging agent in hypoxic myocardium, acutely
ischemic brain and solid tumors [61]. BMS-194796 and
99mTc-HL91 have also been designed as RMIP for imaging
hypoxia, however, none of these three probes has been
commercially available. Iodine-123 labeled iodoazomycin
arabinoside (IAZA) has been validated in animal model in
the preclinical phase [62], but no clinical studies with this
agent have been reported so far.
(5) Cell Labeling. The most common applications of In-111
are in labeling blood cells (white blood cells (WBC) and
platelets) for imaging inﬂammatory processes and thrombi
[63]. In blood cell labeling, the plasma transferrin competes
for the In-111 and reduces the labeling eﬃciency because
In-111 binds with higher eﬃciency to transferrin than
blood cells, and, therefore, isolation of the desired blood
component from plasma permits easy labeling of either
platelets or WBCs. 99mTc-HMPAO is primarily used in brain
perfusion imaging, although it is used for leukocyte labeling
substituting 111In-Oxine. Stabilization of the 99mTc-HMPAO
primary complex is required due to the high degradation
rate of its radiochemical purity. This could be achieved byInternational Journal of Molecular Imaging 9
Table 3: Tc99m- and In-111-labeled peptides.
Compound Description Uses Remarks
In-111 labeled compounds
In-111
pentetreotide
(OctreoScan)
111In has been conjugated to
octreotide as DTPA chelated
compound to form the labeled
somatostatin tracer
(111In-DTPA-octeriotide).
Octreoscan is an agent designed for
the scintigraphic localization of
primary and metastatic somatostatin
receptor positive neuroendocrine
tumors, such as carcinoids,
gastrinoma, neuroblastomas,
pituitary adenomas, and medullary
thyroid carcinomas [44].
Pentetreotide only binds with high
aﬃnity to the somatostatin receptor
subtype SSTR2 with moderate
aﬃnity to SSTR3 and SSTR5 and
not to SSTR1 and SSTR4 [30].
In-111
lanreotide
(Somatuline)
This peptide is modiﬁed with
DOTA and labeled with 111In in a
similar way as octreotide [45, 46].
The high binding aﬃnity of lanreotide to SSTR3 and SSTR4 makes it
suitable to be used as a proper agent for visualization of certain tumors,
such as intestinal adenocarcinomas which is not visualized by
111In-pentetreotide scintigraphy [47].
99mTc-labeled peptides
Depreotide
(NeoSpect)
Depreotide is a synthetic peptide
that binds with high aﬃnity to
somatostatin receptors (SSTR) in
normal as well as abnormal
tissues it has been shown that. It
accumulate in pulmonary
nodules 1.5–2 hours following
the i.v injection [48].
This agent is used to detect
SSTR-bearing pulmonary masses in
p a t i e n t sp r o v e no rs u s p e c t e dt oh a v e
pulmonary lesions by CT and/or
chest X-ray. Negative results with
99mTc-Depreotide can exclude
regional lymph node metastasis with
a high degree of probability [49].
Labeling of the depreotide (cyclic
decapeptide) with 99mTc is
performed by ligand exchange of
intermediary 99mTc-glucoheptonate
[50].
Apcitide
(AcuTect)
The kit vial contains a lyophilized
mixture of depreotide, sodium
glucoheptonate, stannous
chloride, and sodium EDTA.
99mTc-apticide binds to the GP IIb/IIIa receptors on activated platelets
that are responsible for aggregation in forming the thrombi and,
therefore, is used for the detection of acute deep vein thrombosis (DVT)
in lower extremities [28].
adding stabilizers like methylene blue in phosphate buﬀer or
cobalt (II)-chloride to the reaction vials [64], however, these
reagents should not be used when the complex formulation
is designed for labeling of leukocytes.
(6) Iodine-123 as an RMIP. I-123 is the preferred thyroid
imaging agent imparting 1% of thyroid dose per microcurie
when compared with I-131. 123I-labeled compounds are
commonly used as 123I-MIBG for adrenal scan, 123I-OIH for
tubular renal scan, and 123I-iodoamphetamine (123I- IMP)
for cerebral perfusion scan [28].
123I-Ioﬂupane (DaTScan) is a widely used 123I derivative
for detection of the loss of nerve cells in an area of the
brain called the striatum which release dopamine, a chemical
messenger, and therefore, it will be useful in distinguishing
between Parkinson’s disease and essential tremor (tremors
of unknown cause) with a sensitivity of 96.5% [65]. It
is also used to help distinguish between “dementia with
lewy bodies” and Alzheimer’s disease with 75.0% to 80.25%
sensitivity [66].
Dopamine transporter (DAT) imaging with tropane
derivatives such as FP-CIT (123I-Ioﬂupane) and β-CIT
has been developed to directly measure degeneration of
dopamine presynaptic terminal and may be used to quantify
changes in DAT density. Ioﬂupane binds speciﬁcally to
structures of the nerve cells ending in the striatum area
of the brain that are responsible for the transportation of
dopamine. This binding can be detected using tomographic
imaging [67].
4. SPECTinPreclinicalApplications
The application for imaging modalities in preclinical models
is highly valuable as it has a great scope for noninvasively
studying dynamic biological processes at the molecular and
cellular level. The noninvasive nature of imaging provides
advantages in investigating the onset and the progression of
disease, assessing the biological eﬀects of drug candidates
and assisting in the development of disease biomarkers and
monitoring the therapeutic eﬀectiveness of new treatment
and/or pharmaceuticals. This technology plays a key role
in bridging bench studies of disease modelled in vitro to
their implementation in clinically relevant animal models
of diagnostic or therapeutics for their translation into the
clinics. In fact, the implementation of imaging in rodents
has a great relevance because of the widespread use of
genetically modiﬁed mice in biomedical research and the
need to characterise the in vivo anatomical and functional
phenotypes of animal disease models. Another advantage
of imaging modalities developed for small animals is that
the technology can relatively be translated directly for
application to clinical practice.
4.1. Cardiovascular Imaging. Preclinical SPECT systems have
a great scope of applications in cardiovascular research,10 International Journal of Molecular Imaging
including the study of myocardial functions (e.g., ejection
fraction, regional wall motion abnormalities, perfusion, tis-
sue viability, oxygen consumption, and glucose metabolism
[68]) and the investigation of several vascular disorders,
including coronary artery disease and related disorders, such
as ischemia, infarction and atherosclerosis [69]. Moreover,
μSPECT has great applications for developing and testing
diagnostic tracers which could assist in understanding
the prognosis of disorders and assess new therapeutic
approaches for cardiovascular lesions.
99mTc-labelled radiopharmaceuticals for SPECT imaging
have been applied to demonstrate tissue viability and per-
fusion status in animal models of ischemia and/or impaired
myocardial perfusion [70, 71]. Cardiac and respiratory
motion is one of the major challenges when imaging rodent
(mouse heart rate: 400–800 beats/min). Gated acquisition
is therefore required to minimise any movement artefacts.
Indeed, ECG-gated micro SPECT can yield accurate mea-
surements of left ventricle volumes and ejection fraction in
rats and mice [72, 73].
Another key area is the visualization of necrotic tissues
and related tracers during myocardial infarction (MI). Some
studieshaveassessedmyocardialischemiainratheartmodels
after left coronary artery occlusion by using 99mTc-glucarate
[74]. In vivo visualization of necrosis may help to detect
MI at early stages and may provide a good approach for
evaluating the antinecrotic eﬀect of developing drugs for
ischemic heart disease. On the same vein, the visualization
of apoptotic cell death is another important target for non-
invasive imaging [75]. Hence, the development of tracers
(e.g.,99mTc-Annexin) that bind to apoptotic cells is a very
useful tool for in vivo analysis, especially to investigate
apoptotic cell death in cardiomyocytes and the eﬃcacy of
cell-based therapies.
Angiogenesis imaging is a key protective/remodelling
mechanism in myocardial infarction. Imaging such a mecha-
nism is important for the understanding of infarct healing
and post-MI remodelling. Vascular growth factors such
as αvβ3 integrins have been used as targeted tracers to
investigate angiogenesis in postinfarct animal models, with
In-111-labelled αvβ3 targeted radiotracers in hypoperfused
myocardial regions [76].
Another relevant area of cardiovascular imaging is the
development of methods to characterise the formation and
prognosis of atherosclerotic plaques. Plaque rupture results
in severe cardiac events including MI and sudden death,
hence, there is an important need for developing tools that
can assist in predicting the plaques vulnerability to rupture.
Not all the plaques carry the same risk, and the criteria for
imaging their vulnerability relies on the detection of inﬂam-
matory cell inﬁltration, platelet aggregation, tissue matrix
degradation,largelipidcontentsandapoptosis.Radiolabeled
Annexin and Z2D3 targeted to apoptotic macrophages and
smooth muscle cells, respectively, have been used as SPECT
tracers to study the pathophysiology of atherosclerosis in
animal models [77, 78]. One of the main challenges for
imaging plaques is their anatomical localization, as high
spatial resolution is needed to image such a small anatomical
structure in a motile vessel, hence the importance of co-
registering SPECT acquisition with other imaging modalities
such as micro-CT.
4.2. Imaging Stem Cells. With advances in research of stem
cell-based therapies, the application of imaging technologies
may be useful to validate their eﬃcacy and safety in
preclinical models, in particular, for studying tracking and
engraftment of transplanted cells, assessing their viability,
function and diﬀerentiation status in addition to monitoring
their ability to promote regeneration [79]. Stem cells can
be labelled with radionuclides before transplantation. For
example, stem cells labelled with the SPECT radiolabels
111In-oxyquinoline have been successfully imaged after
transplantation in rat and porcine models of myocardial
infarction [80, 81], but, because of the short half-life of the
radionuclide (e.g., 99mTc: 6.02h; 111In: 2.8 days) and because
the activity may still be present after transplantation even if
the cell have died, this method may only be applicable for a
short-term cell tracking and assessing stem cell homing after
transplantation.
To investigate not only long-term engraftment of stem
cells but also their viability, a gene imaging approach may be
more appropriate. In this case, gene expression is assessed by
reporter genes constructs which are translated into a protein
and interact with an exogenously given probe (radiolabeled
for SPECT detection), resulting in a signal that can be
monitored non-invasively. Reporter genes are incorporated
into the cells before transplantation, and if the cell remains
alive after engraftment, the protein, which is the main target
for the nuclides, will be encoded (e.g., enzyme, cell surface
receptor). Conversely, the reporter gene will not be expressed
if the cell is dead [82].
As mentioned earlier, one of the reporter genes mostly
used for SPECT imaging is based on the production of
an intracellular enzyme (e.g., herpes simplex virus type 1
thymidine kinase [HSV1tk]) that phosphorylates an exoge-
nously administered substrate that is retained in the cell
because of its negative charge. Although normal mammalian
cells (without the HSV1-tk) do carry the enzyme, it only
minimally phosphorylates the radionuclide probes used in
this system. Conversely, in cells carrying the HSV1-tk, the
exogenously administered probe undergoes signiﬁcant phos-
phorylation and intracellular retention, leading to a robust
signal-to-background ratio and enabling accurate monitor-
ing of these cells [83]. This imaging approach has been
recently used to monitor the distribution of transplanted
humanembryonicstemcellderivativesinalivemousemodel
over a long period of time, up to 3 months [84].
Another approach consists of the encoding of the
sodium-iodide symporter (NIS), a thyroid transmembrane
protein that, under physiologic conditions, transports iodine
into the cells in exchange for sodium. It has the advantage
that it can be used for PET (with 124I as the tracer)
and SPECT imaging (using 123Io r99mTc-pertechnetate as
tracer). This approach has been used to monitor activity
of cardiac-derived stem cells after transplantation to a rat
infarct model, conﬁrming the visualization of cells up to
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stem cell research, and with high demands for testing their
regenerative potential in preclinical model, noninvasive stem
cell imaging will play a critical role, and we can foresee
more studies requiring long-term monitoring of stem cells
in preclinical models of disease.
4.3. Oncologic Applications. Imaging techniques play a po-
tential role in preclinical cancer research, enabling sequential
analysis of deep-seated tumors and metastases including
studies of basic biological processes, tissue pharmacokinetics
and pharmacodynamics responses to treatments. Imaging
of cancer cells targets have diﬀerent biological procedures
including overexpression of receptor, activated enzymes or
relocatedmolecules,apoptoticlevels,sustainedangiogenesis,
unlimited replicative potential and invasion of tissue, and
metastasis [86].
Imaging gene expression in vivo is very relevant in
cancer preclinical models as it allows the characterization of
dynamic changes in several deregulated pathways in cancer
cells. As previously mentioned, HSVtk genes are typically
used for SPECT, enabling noninvasive imaging of tumor cell
growthasdemonstratedinanexperimentalmousemodelfor
lung metastases expressing after injection of HSV1-tk cells
[87].This model maybe provenveryusefulforassessment of
anticancerandantimetastasestherapiesinpreclinicaleﬃcacy
models.
Another used approach is the imaging receptors that
are overexpressed in cancer cells and can be used for
prognosis and for following therapeutic targeting. This has
been successfully applied preclinically as well as clinically
by targeting prostate-speciﬁc membrane antigen (PSMA).
This receptor is overexpressed on the cell surface of prostate
cancer cells and provides a useful target for prostate tumor
imaging and therapy. As mentioned previously, radiolabeled
monoclonal antibodies, such as 111In-Capromab pendetide
(ProstaScint),arecurrentlyavailabletodetectprostatecancer
but suﬀer from problems associated with poor delivery
because of their large size [88]. The feasibility of imaging
PSMAreceptorexpressionwithlow-molecular-weight,high-
aﬃnity PSMA ligands labeled with [125I] NaI/Iodogen for
SPECT was demonstrated in a study using a prostate tumor
mouse model [89].
SPECT technology is extensively used as a diagnostic tool
for bone metastases in the clinic. Bone scintigraphy with
99mTc-labelled diphosphonate is a widely used method for
the detection of bone metastases, and other bone disorders.
This technique provides a high sensitivity and is able to
surveythewholeskeletonbutunfortunatelydoesnotprovide
enough anatomical resolution to allow precise localization
of the radiotracer high uptake lesion. The implementation
of a SPECT/CT multimodality system can partly overcome
this disadvantage, allowing a coregistration of the functional
and the anatomical imaging component, resulting in precise
anatomical localisation of the radiotracer. Studies have
reported the use of Tc-99m-labeled diphosphonates com-
pounds (e.g., methylene-diphosphonate (MDP)) to detect
metastatic bone lesions in immunocompromised mouse
models injected with cancer cells. Overall, the application
of SPECT imaging in cancer research while remaining
challenging have already had a remarkable impact providing
new insights into the dynamics of cancer growth, invasion,
and metastases, being possible to visualize gene expression,
molecular pathways and functional parameters in preclinical
models of cancer.
4.4. Neuroimaging Applications. The use of SPECT in
preclinical functional neuroimaging provides an excellent
applicationforunderstandingthepathophysiologyofcentral
nervous system (CNS) disorders, including the mechanisms
of neurodegeneration, neuropharmacology related to drug
abuse, and testing therapeutic strategies. As mentioned
earlier, one of the strength of SPECT over other functional
modalities such as the PET is the ability to get a spatial
resolution below 1mm, allowing detailed structural and
functional information of diﬀerent region of the brain
in animal models. Also, SPECT radioligands have relative
longer half-lives, which permits prolonged dynamic function
studiesandprovidesasimultaneousdualtracerimaging.The
use of pinhole SPECT facilitates accurate and quantitative
imaging. Indeed, speciﬁc radioligands have been used to
study the dopaminergic, serotonergic, and cholinergic neu-
rotransmission system in vivo [90].
SPECT has been applied to study basic mechanisms of
degeneration in Parkinson’s (PD) and Alzheimer’s disease
(AD).PDischaracterizedbyaprogressivelossofdopaminer-
gic neurons. Animal models of neurodegeneration have been
used to evaluate novel radioligands and to study their bind-
ing in the dopaminergic synapsis. In vivo quantiﬁcation of
the presynaptic dopamine transporter (DAT) activity which
regulatesthesynapticdopamineisfeasibleintheratstriatum
using the 123I-N-ω-ﬂuoropropyl-2β-carbomethoxy-3β-(4-
iodophenyl)-nortropane (123I-FP-CIT) as a DAT radioligand
[91], as outlined earlier. This technology is of particu-
lar interest for investigating the interrelation of synaptic
dopamine and DAT in animal models of PD. Similarly,
Acton et al. have characterized the occupancy of dopamine
r e c e p t o r si nt h em o u s eb r a i n[ 92]. SPECT imaging has
improved the early diagnosis of AD in patients by detecting
the onset of progressive neurodegenerative disorders and
vascular brain pathology causing dementia.
The thioﬂavin derivative, 6-iodo-2-(4 -dimethylamino-)
phenyl-imidazo [1,2-a] pyridine, IMPY, which is readily
radiolabeledwith 125I/123I[ 123I]IMPYwasassessedexvivoin
a transgenic mouse model of AD by labeling the deposition
of amyloid plaque that is linked to the pathogenesis of AD
[93], showing a good binding with brain tissue homogenates
of conﬁrmed Alzheimer’s disease patients. Overall, these
preclinical studies support the use of SPECT for functional
imaging in preclinical models of CNS disorders, facilitating
the eﬃcacy of translational studies into this ﬁeld with a
direct relevance for developing clinical diagnostic tools and
eﬃcacious therapies.
4.5. Drug Discovery. Preclinical imaging has a key role in
the drug development, in particular for validating drug
targeting, safety, and eﬃcacy. One of the main applications12 International Journal of Molecular Imaging
is the validation in drug binding assays to speciﬁc targeted
areas, by directly labeling a drug to determine its distri-
bution and pharmacokinetics. This approach is very useful
for validating delivery roots and the speciﬁcity of novel
therapeutic drugs or imaging agents. SPECT imaging has
been applied to measure the binding potential of targeted
nuclide [123I] Iodobenzamide to the dopamine transporters
in the rat brain after speciﬁc treatments [94]. Similarly,
99mTc-labeled liposomes migration has been studied after
intratumoral administration to tumor xenograft models
in nude rats [95]. Speciﬁc skeletal targeted probes (125I
labeled) were investigated with particular emphasis on the
pharmacokinetics and biodistribution following intravenous
administration. This has proved to be of great potential for
validating the eﬃcacy of animal models of osteoporosis and
other skeletal diseases [96].
Imaging technologies are also very useful for safety
validation, as they can measure the functional response of
organs to a tested drug candidate, providing information
on any toxic or secondary eﬀects related to the treatment.
Radiopharmaceuticals that bind to apoptotic cells (e.g.,
99mTc-Annexin) have been used preclinically to validate the
possible toxicity eﬀects in developing therapies [97]. Other
examples on secondary response to the administration of a
candidate drug in preclinical models include measurements
in blood ﬂow changes [98] and inﬁltration of inﬂammatory
cells [99].
Another important application is the development and
validation of imaging biomarkers, a surrogate imaging
product that simulates a biological compound and/or has
some biologic link to the disease process. These biomarkers
are becoming very useful to assess therapeutic actions of
pharmaceuticals, providing a non-invasive imaging tool for
validating the eﬃcacy of treatment. Advances in proteomics
andgenomicsareleadingtothediscoveryofnewbiomarkers,
promoting the use of functional imaging for their validation
and translation into the clinics [100].
5. Conclusion
SPECT imaging has a well-deﬁned role in the world of
molecular imaging. Recent advances in dedicated preclinical
systems are able to provide high spatial and temporal resolu-
tion as well as high detection eﬃciency with more potentiall
for further improvement. Hybrid SPECT imaging systems
would serve characterizing biological phenomena in one
imaging session. Reliable animal models that, mimic human
diseases is another innovative ﬁeld that when combined
with SPECT technology will reveal more insights into early
disease detection, development of new tracers/therapeutics
and treatment strategy. SPECT imaging has a large potential
in molecular medicine, and many novel approaches are
expected in the near future.
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